- Description
- Table of Contents
- Request Sample
The CAR T-Cell Therapy market is expected to reach $13,617.10 million by 2026 growing at a CAGR of 56.2% from 2018 to 2026. Chimeric Antigen Receptor (CAR) T Cell Therapy is a type of treatment in which patient T cells are changed in the laboratory to attack the cancer cells. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells. CAR T-cell therapy uses patients own modified white blood cells to kill the cancer cells. CAR T-cell therapy is moreover a living drug and its benefits can last for many years. CAR T cell therapy is used in curing patients with breast cancer, pancreas cancer, colorectal cancer and various types of blood cancer. Factors such as technological advancement for advanced & reliable treatment for cancer, growing pharmaceutical industry, high prevalence of acute lymphoblastic lymphoma (ALL) and increase in the number of cell therapy clinical studies are fuelling the market growth. However, side-effects of CAR T-cell therapy and high cost of treatment are likely to hamper the market growth. Based on the application, diffuse large B-cell lymphoma is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, though it can also occur in children and young adults in rare cases. DLBCL is an aggressive tumour which can arise in virtually any part of the body, and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with B symptoms of fever, weight loss, and night sweats. The key vendors mentioned are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc., Pfizer, Inc., Juno Therapeutics, Atara Biotherapeutics, Aurora Biopharma Inc., Eureka Therapeutics, Autolus, TILT Biotherapeutics, and Fortress Biotech. Target Antigens Covered: • CD20 • EGFRV III • CD19 • HER2 • MESO • CD22 • BCMA • GD2 • CD30 • HER1 • CD33 Products Covered: • Allogeneic • Autologous Therapies Covered • Axicabtagene Ciloleucel (Yescarta) • Tisagenlecleucel (Kymriah) Applications Covered: • Chronic Lymphocytic Leukemia • Diffuse Large B-Cell Lymphoma • Multiple Myeloma • Acute Lymphoblastic Leukemia • Follicular Lymphoma • Mantle Cell Lymphoma • Glioblastoma • Neuroblastoma • Breast Cancer • Sarcoma • Acute Myeloid Leukemia • Colorectal Cancer • Pancreatic Cancer • Hepatocellular Carcinoma • Non-Hodgkin Leukemia • Carcinoma End Users Covered • Cancer Research Centers • Hospitals • Academic and Research Institutes • Pharmaceutical Companies • Biotechnology Companies • Contract Research Organizations Regions Covered: • North America • Europe • Asia Pacific • South America • Middle East & Africa Key Questions Answered in this Report: • How this market evolved since the year 2016 • Market size estimations, forecasts and CAGR for all the segments presented in the scope • Key Market Developments and financials of the key players • Opportunity Analysis for the new entrants • SWOT Analysis of the key players • Fastest growing markets analysed during the forecast period
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global CAR T-Cell Therapy Market, By Target Antigen
5.1 Introduction
5.2 CD20
5.3 EGFRV III
5.4 CD19
5.5 HER2
5.6 MESO
5.7 CD22
5.8 BCMA
5.9 GD2
5.10 CD30
5.11 HER1
5.12 CD33
6 Global CAR T-Cell Therapy Market, By Product
6.1 Introduction
6.2 Allogeneic
6.3 Autologous
7 Global CAR T-Cell Therapy Market, By Therapy
7.1 Introduction
7.2 Axicabtagene Ciloleucel (Yescarta)
7.3 Tisagenlecleucel (Kymriah)
8 Global CAR T-Cell Therapy Market, By Application
8.1 Introduction
8.2 Chronic Lymphocytic Leukemia
8.3 Diffuse Large B-Cell Lymphoma
8.4 Multiple Myeloma
8.5 Acute Lymphoblastic Leukemia
8.6 Follicular Lymphoma
8.7 Mantle Cell Lymphoma
8.8 Glioblastoma
8.9 Neuroblastoma
8.10 Breast Cancer
8.11 Sarcoma
8.12 Acute Myeloid Leukemia
8.13 Colorectal Cancer
8.14 Pancreatic Cancer
8.15 Hepatocellular Carcinoma
8.16 Non-Hodgkin Leukemia
8.17 Carcinoma
9 Global CAR T-Cell Therapy Market, By End User
9.1 Introduction
9.2 Cancer Research Centers
9.3 Hospitals
9.4 Academic and Research Institutes
9.5 Pharmaceutical Companies
9.6 Biotechnology Companies
9.7 Contract Research Organizations
10 Global CAR T-Cell Therapy Market, By Geography
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 South America
10.6 Middle East & Africa
11 Strategic Benchmarking
12 Vendors Landscape
12.1 Mustang Bio, Inc.
12.2 Celgene Corporation
12.3 Bluebird Bio, Inc.
12.4 CARsgen Therapeutics, Ltd.
12.5 Novartis International AG
12.6 Legend Biotech
12.7 Sorrento Therapeutics Inc.
12.8 Kite Pharma, Inc.
12.9 Immune Therapeutics
12.10 Bellicum Pharmaceuticals, Inc.
12.11 Pfizer, Inc.
12.12 Juno Therapeutics
12.13 Atara Biotherapeutics
12.14 Aurora Biopharma Inc.
12.15 Eureka Therapeutics
12.16 Autolus
12.17 TILT Biotherapeutics
12.18 Fortress Biotech
List of Data Tables
Table 1 Global CAR T-Cell Therapy Market Outlook, By Region (2016-2026) ($MN)
Table 2 Global CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
Table 3 Global CAR T-Cell Therapy Market Outlook, By CD20 (2016-2026) ($MN)
Table 4 Global CAR T-Cell Therapy Market Outlook, By EGFRV III (2016-2026) ($MN)
Table 5 Global CAR T-Cell Therapy Market Outlook, By CD19 (2016-2026) ($MN)
Table 6 Global CAR T-Cell Therapy Market Outlook, By HER2 (2016-2026) ($MN)
Table 7 Global CAR T-Cell Therapy Market Outlook, By MESO (2016-2026) ($MN)
Table 8 Global CAR T-Cell Therapy Market Outlook, By CD22 (2016-2026) ($MN)
Table 9 Global CAR T-Cell Therapy Market Outlook, By BCMA (2016-2026) ($MN)
Table 10 Global CAR T-Cell Therapy Market Outlook, By GD2 (2016-2026) ($MN)
Table 11 Global CAR T-Cell Therapy Market Outlook, By CD30 (2016-2026) ($MN)
Table 12 Global CAR T-Cell Therapy Market Outlook, By HER1 (2016-2026) ($MN)
Table 13 Global CAR T-Cell Therapy Market Outlook, By CD33 (2016-2026) ($MN)
Table 14 Global CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
Table 15 Global CAR T-Cell Therapy Market Outlook, By Allogeneic (2016-2026) ($MN)
Table 16 Global CAR T-Cell Therapy Market Outlook, By Autologous (2016-2026) ($MN)
Table 17 Global CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
Table 18 Global CAR T-Cell Therapy Market Outlook, By Axicabtagene Ciloleucel (Yescarta) (2016-2026) ($MN)
Table 19 Global CAR T-Cell Therapy Market Outlook, By Tisagenlecleucel (Kymriah) (2016-2026) ($MN)
Table 20 Global CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
Table 21 Global CAR T-Cell Therapy Market Outlook, By Chronic Lymphocytic Leukemia (2016-2026) ($MN)
Table 22 Global CAR T-Cell Therapy Market Outlook, By Diffuse Large B-Cell Lymphoma (2016-2026) ($MN)
Table 23 Global CAR T-Cell Therapy Market Outlook, By Multiple Myeloma (2016-2026) ($MN)
Table 24 Global CAR T-Cell Therapy Market Outlook, By Acute Lymphoblastic Leukemia (2016-2026) ($MN)
Table 25 Global CAR T-Cell Therapy Market Outlook, By Follicular Lymphoma (2016-2026) ($MN)
Table 26 Global CAR T-Cell Therapy Market Outlook, By Mantle Cell Lymphoma (2016-2026) ($MN)
Table 27 Global CAR T-Cell Therapy Market Outlook, By Glioblastoma (2016-2026) ($MN)
Table 28 Global CAR T-Cell Therapy Market Outlook, By Neuroblastoma (2016-2026) ($MN)
Table 29 Global CAR T-Cell Therapy Market Outlook, By Breast Cancer (2016-2026) ($MN)
Table 30 Global CAR T-Cell Therapy Market Outlook, By Sarcoma (2016-2026) ($MN)
Table 31 Global CAR T-Cell Therapy Market Outlook, By Acute Myeloid Leukemia (2016-2026) ($MN)
Table 32 Global CAR T-Cell Therapy Market Outlook, By Colorectal Cancer (2016-2026) ($MN)
Table 33 Global CAR T-Cell Therapy Market Outlook, By Pancreatic Cancer (2016-2026) ($MN)
Table 34 Global CAR T-Cell Therapy Market Outlook, By Hepatocellular Carcinoma (2016-2026) ($MN)
Table 35 Global CAR T-Cell Therapy Market Outlook, By Non-Hodgkin Leukemia (2016-2026) ($MN)
Table 36 Global CAR T-Cell Therapy Market Outlook, By Carcinoma (2016-2026) ($MN)
Table 37 Global CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
Table 38 Global CAR T-Cell Therapy Market Outlook, By Cancer Research Centers (2016-2026) ($MN)
Table 39 Global CAR T-Cell Therapy Market Outlook, By Hospitals (2016-2026) ($MN)
Table 40 Global CAR T-Cell Therapy Market Outlook, By Academic and Research Institutes (2016-2026) ($MN)
Table 41 Global CAR T-Cell Therapy Market Outlook, By Pharmaceutical Companies (2016-2026) ($MN)
Table 42 Global CAR T-Cell Therapy Market Outlook, By Biotechnology Companies (2016-2026) ($MN)
Table 43 Global CAR T-Cell Therapy Market Outlook, By Contract Research Organizations (2016-2026) ($MN)
Table 44 North America CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
Table 45 North America CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
Table 46 North America CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
Table 47 North America CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
Table 48 North America CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
Table 49 Europe CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
Table 50 Europe CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
Table 51 Europe CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
Table 52 Europe CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
Table 53 Europe CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
Table 54 Asia Pacific CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
Table 55 Asia Pacific CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
Table 56 Asia Pacific CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
Table 57 Asia Pacific CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
Table 58 Asia Pacific CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
Table 59 South America CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
Table 60 South America CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
Table 61 South America CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
Table 62 South America CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
Table 63 South America CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)
Table 64 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Target Antigen (2016-2026) ($MN)
Table 65 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Product (2016-2026) ($MN)
Table 66 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Therapy (2016-2026) ($MN)
Table 67 Middle East & Africa CAR T-Cell Therapy Market Outlook, By Application (2016-2026) ($MN)
Table 68 Middle East & Africa CAR T-Cell Therapy Market Outlook, By End User (2016-2026) ($MN)